Biocon Net Profit Jumps 105% To Rs 254 Crore In March Quarter
Biocon Limited- the country's leading biopharmaceutical company, reported a 105 per cent growth in net profit to Rs 254 crore for the January-March quarter in the financial year 2020-21, compared to Rs 123 crore in the corresponding period last year. The Bengaluru-based company's revenue during the March quarter grew 26 per cent to Rs 2,044 crore, tracking higher growth in its biosimilar, research services, and generic business. Biocon is involved in manufacturing generic active pharmaceutical ingredients and is an innovation-led integrated company.
According to a regulatory filing by the firm to the BSE on Thursday, April 29, Biocon's consolidated revenue increased 26 per cent in the fourth quarter of the fiscal 2020-21 to Rs 2,044 crore, compared to Rs 1,621 crore in the corresponding quarter last year.
Amid the second wave of the COVID-19 pandemic in the country, the company's subsidiary Biocon Biologics, stepped up to provide the anti-CD6 novel biologic Itolizumab or ALZUMAb-L for infected patients. According to the statement, ALZUMAb-L was approved by the Drug Controller General of India for restricted emergency use.
Biocon added that due to the uncertainty of the second wave of the pandemic and considering the investments in R&D, the board of directors decided not to declare a dividend for the financial year 2020-21.Â
Biocon is listed on stock exchanges BSE and NSE. After reporting the March quarter results, the share price of Biocon Limited edged marginally higher. On Thursday, Biocon opened at Rs 387.20 on the BSE, registering an intra day high of Rs 402.10 and an intra day low of Rs 386 during the session. Shares of Biocon settled 0.77 per cent higher at Rs 393.95 apiece on the BSE. On the NSE, shares of Biocon settled 0.81 per cent higher at Rs 394 apiece.Â
-
Opinion | India at 38: From Innovation Overperformer to Innovation Powerhouse
India now has 453 VC-backed deep science startups, 18 of them late-stage, after 117 percent growth since 2020. Laurus Labs, at USD 9.3 billion, is the most valuable deep science company in any middle-income economy outside China.
-
Navigating Energy Crossroads: S Jaishankar's Call For Diversified Supply Chains At G20 Ministerial Meeting
As geopolitical fault lines continue to test maritime trade routes and commodity flows, Jaishankar's message remains pertinent: true economic resilience requires open markets, protected transit lines, and a genuine commitment to multilateral cooperation rather than coercion.
-
Indians Are Travelling, But Not Every Journey Is A Holiday | The Week In Whys
Pilgrims, patients and working women are the real travellers, and the system hasn't quite caught up with them.
-
Getting To Work Costs Women More | The Reason Why
It is not just about women paying more than men. It is about women paying much more in cities than in villages.
-
AI Bias In Investing Cannot Be Eliminated, But It Can Be Governed
Framing is a particularly important example as identical financial information presented in terms of gains rather than losses can lead an LLM to reach a different assessment.
-
Joining The Dots | Dark Skies, Steady Diya: Why Hope Holds This Diwali
With war, a weak rupee and foreign outflows weighing on sentiment, policymakers at the NDTV World Summit and market veterans at NDTV Profit Ignite: Diwali Edition offered the same advice: stay invested and filter out the noise.
-
The Curious Case of Equitas Small Finance Bank And A CEO Who Quit For Stock
PN Vasudevan believes persistent investor concerns over a perceived conflict of interest had become a governance overhang on Equitas Small Finance Bank's stock, even as the lender improved profitability and asset quality.
-
Talking Points This Week: AI Cash Burn, A Tiger Comeback And An India That Still Finds Its Own Path
India is not immune to higher oil or tighter global liquidity, yet its earnings base is broader, its domestic policy levers are still available.
-
Foreign Investors Own Half Of HDFC Bank and ICICI Bank. An LTCG Cut Could Matter Most Here
Foreign portfolio investors have US$115 billion parked in HDFC Bank, ICICI Bank. If the government cuts long-term capital gains tax, Jefferies says returning foreign money could land here first.
